Table 1.
Demographic and baseline disease characteristics by sex
| Characteristic mean (SD) unless specified otherwise | Any secukinumab | Placebo | P value* | ||
|---|---|---|---|---|---|
| Male N = 642 |
Female N = 243 |
Male N = 389 |
Female N = 153 |
||
| Age (years) | 38.9 (11.4) | 41.6 (12.2) | 39.1 (12.4) | 43.5 (12.6) | < 0.0001 |
| Weight (kg) | 79.7 (18.4) | 70.8 (17.8) | 78.6 (15.1) | 71.4 (16.5) | < 0.0001 |
| BMI (kg/m2) | 26.2 (5.5) | 26.6 (6.3) | 25.9 (4.5) | 27.0 (6.1) | 0.0307 |
| Current smoking (yes), n (%) | 239 (37.2) | 42 (17.3) | 148 (38.0) | 33 (21.6) | < 0.0001 |
| Time since first diagnosis of AS (years) | 6.5 (7.7) | 6.0 (7.6) | 6.8 (8.2) | 6.2 (7.5) | 0.2322 |
| hs-CRP (mg/L) | 18.3 (28.2) | 10.7 (18.1) | 17.9 (22.9) | 10.0 (14.8) | < 0.0001 |
| TNFi naïve, n (%) | 489 (76.2) | 170 (70.0) | 297 (76.3) | 101 (66.0) | 0.0026 |
| MASES | 2.4 (3.1) | 4.6 (3.8) | 2.3 (3.0) | 4.9 (3.9) | < 0.0001 |
| ASDAS-CRP | 3.81 (0.8) | 3.6 (0.9) | 3.83 (0.9) | 3.65 (0.8) | < 0.0001 |
| BASDAI | 6.7 (1.4) | 7.1 (1.4) | 6.7 (1.3) | 7.1 (1.4) | < 0.0001 |
| BASMI linear (cm) | 3.9 (1.8) | 3.3 (1.4) | 3.9 (1.7) | 3.5 (1.5) | < 0.0001 |
| BASMI occiput-to-wall distance (cm) | 4.8 (6.0) | 2.6 (4.2) | 5.3 (7.3) | 2.5 (4.0) | < 0.0001 |
| BASMI tragus-to-wall distance (cm) | 14.7 (5.2) | 12.1 (2.9) | 15.2 (5.3) | 12.5 (3.3) | < 0.0001 |
| BASFI | 6.1 (2.0) | 6.3 (2.1) | 6.1 (1.9) | 6.1 (2.2) | 0.3065 |
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, hs-CRP high sensitivity C-reactive protein, PBO placebo, SD standard deviation, TNFi tumor necrosis factor inhibitor